197 related articles for article (PubMed ID: 29038000)
1. Epigenetic regulation of miR-200 as the potential strategy for the therapy against triple-negative breast cancer.
Mekala JR; Naushad SM; Ponnusamy L; Arivazhagan G; Sakthiprasad V; Pal-Bhadra M
Gene; 2018 Jan; 641():248-258. PubMed ID: 29038000
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic modulations in triple-negative breast cancer: Therapeutic implications for tumor microenvironment.
Zhou L; Yu CW
Pharmacol Res; 2024 Jun; 204():107205. PubMed ID: 38719195
[TBL] [Abstract][Full Text] [Related]
3. Apigenin and its combination with Vorinostat induces apoptotic-mediated cell death in TNBC by modulating the epigenetic and apoptotic regulators and related miRNAs.
Nimal S; Kumbhar N; Saruchi ; Rathore S; Naik N; Paymal S; Gacche RN
Sci Rep; 2024 Apr; 14(1):9540. PubMed ID: 38664447
[TBL] [Abstract][Full Text] [Related]
4. Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator.
Karati D; Mukherjee S; Roy S
Med Oncol; 2024 Mar; 41(4):84. PubMed ID: 38438564
[TBL] [Abstract][Full Text] [Related]
5. Spatiotemporal quantitative microRNA-155 imaging reports immune-mediated changes in a triple-negative breast cancer model.
Skourti E; Volpe A; Lang C; Johnson P; Panagaki F; Fruhwirth GO
Front Immunol; 2023; 14():1180233. PubMed ID: 37359535
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic modifiers synergize with immune-checkpoint blockade to enhance long-lasting antitumor efficacy.
Baretti M; Yarchoan M
J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34396984
[TBL] [Abstract][Full Text] [Related]
7. EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities.
Yedier-Bayram O; Gokbayrak B; Kayabolen A; Aksu AC; Cavga AD; Cingöz A; Kala EY; Karabiyik G; Günsay R; Esin B; Morova T; Uyulur F; Syed H; Philpott M; Cribbs AP; Kung SHY; Lack NA; Onder TT; Bagci-Onder T
Cell Death Dis; 2022 Aug; 13(8):710. PubMed ID: 35973998
[TBL] [Abstract][Full Text] [Related]
8. Targeting microRNAs: a new action mechanism of natural compounds.
Lin Q; Ma L; Liu Z; Yang Z; Wang J; Liu J; Jiang G
Oncotarget; 2017 Feb; 8(9):15961-15970. PubMed ID: 28052018
[TBL] [Abstract][Full Text] [Related]
9. microRNA-130a suppresses breast cancer cell migration and invasion by targeting FOSL1 and upregulating ZO-1.
Chen X; Zhao M; Huang J; Li Y; Wang S; Harrington CA; Qian DZ; Sun XX; Dai MS
J Cell Biochem; 2018 Jun; 119(6):4945-4956. PubMed ID: 29384218
[TBL] [Abstract][Full Text] [Related]
10. HDAC inhibitor suppresses proliferation and invasion of breast cancer cells through regulation of miR-200c targeting CRKL.
Bian X; Liang Z; Feng A; Salgado E; Shim H
Biochem Pharmacol; 2018 Jan; 147():30-37. PubMed ID: 29155146
[TBL] [Abstract][Full Text] [Related]
11. MiR-200 family and cancer: From a meta-analysis view.
Huang GL; Sun J; Lu Y; Liu Y; Cao H; Zhang H; Calin GA
Mol Aspects Med; 2019 Dec; 70():57-71. PubMed ID: 31558294
[TBL] [Abstract][Full Text] [Related]
12. The microRNAs miR-200b-3p and miR-429-5p target the LIMK1/CFL1 pathway to inhibit growth and motility of breast cancer cells.
Li D; Wang H; Song H; Xu H; Zhao B; Wu C; Hu J; Wu T; Xie D; Zhao J; Shen Q; Fang L
Oncotarget; 2017 Oct; 8(49):85276-85289. PubMed ID: 29156719
[TBL] [Abstract][Full Text] [Related]
13. MicroRNAs in regulation of triple-negative breast cancer progression.
Piasecka D; Braun M; Kordek R; Sadej R; Romanska H
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1401-1411. PubMed ID: 29923083
[TBL] [Abstract][Full Text] [Related]
14. Regulatory roles of the miR-200 family in neurodegenerative diseases.
Fu J; Peng L; Tao T; Chen Y; Li Z; Li J
Biomed Pharmacother; 2019 Nov; 119():109409. PubMed ID: 31518873
[TBL] [Abstract][Full Text] [Related]
15. Liver X Receptors (LXRs) in cancer-an Eagle's view on molecular insights and therapeutic opportunities.
Ramalingam PS; Elangovan S; Mekala JR; Arumugam S
Front Cell Dev Biol; 2024; 12():1386102. PubMed ID: 38550382
[TBL] [Abstract][Full Text] [Related]
16. Cancer metastasis under the magnifying glass of epigenetics and epitranscriptomics.
Janin M; Davalos V; Esteller M
Cancer Metastasis Rev; 2023 Dec; 42(4):1071-1112. PubMed ID: 37369946
[TBL] [Abstract][Full Text] [Related]
17. New Biomarkers and Treatment Advances in Triple-Negative Breast Cancer.
El Hejjioui B; Lamrabet S; Amrani Joutei S; Senhaji N; Bouhafa T; Malhouf MA; Bennis S; Bouguenouch L
Diagnostics (Basel); 2023 Jun; 13(11):. PubMed ID: 37296801
[TBL] [Abstract][Full Text] [Related]
18. microRNA-497 slows esophageal cancer development and reverses chemotherapy resistance through its target QKI.
Xie YX; Zhou ZH; Liu SW; Zhang Y; Liu WJ; Zhang RK; He ML; Qiu JG; Wang L; Jiang BH
Aging (Albany NY); 2023 May; 15(9):3791-3806. PubMed ID: 37171386
[TBL] [Abstract][Full Text] [Related]
19. Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA.
Szczepanek J; Skorupa M; Jarkiewicz-Tretyn J; Cybulski C; Tretyn A
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108398
[TBL] [Abstract][Full Text] [Related]
20. An Update of Epigenetic Drugs for the Treatment of Cancers and Brain Diseases: A Comprehensive Review.
Sahafnejad Z; Ramazi S; Allahverdi A
Genes (Basel); 2023 Apr; 14(4):. PubMed ID: 37107631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
